olanzapine, Zyprexa, Zydis, Zyprexa Relprevv (cont.)

Pharmacy Author:
Medical and Pharmacy Editor:

There may be an increased risk of elevated blood sugar levels and diabetes with olanzapine as well as the other antipsychotic medications in its class. Patients should be tested during treatment for elevated blood sugar. Additionally, persons with risk factors for diabetes, including obesity or a family history of diabetes, should have their fasting levels of blood sugar tested before starting treatment and periodically throughout treatment to detect the onset of diabetes. Any patient developing symptoms that suggest diabetes during treatment should be tested for diabetes.

Patients may develop severe sedation, coma, and or delirium after an injection of extended release olanzapine. Patients must be examined for 3 hours after receiving an injection.

Elderly patients with dementia related psychosis treated with antipsychotics are at an increased risk of death.

Olanzapine may increase prolactin levels. Increased prolactin levels may manifest as abnormal menstruation, sexual dysfunction, and breast enlargement.



PREPARATIONS: Tablets: 2.5, 5, 7.5, 10, 15, 20 mg. Tablets (orally disintegrating): 5, 10, 15, 20 mg. Injection (immediate release): 10 mg vial. Suspension for Injection (extended release): 210, 300, and 405 mg (powder).

STORAGE: Tablets should be kept at room temperature, 20 C - 25 C (68 F - 77 F). Suspension is stored at room temperature not to exceed 30 C (86 F).

Medically Reviewed by a Doctor on 1/12/2015

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.

Back to Medications Index